130 related articles for article (PubMed ID: 37088650)
1. Women with type 2 diabetes have LDL cholesterol levels higher than those of men, regardless of their treatment and their cardiovascular risk level.
Paquet S; Sassenou J; Ringa V; Czernichow S; Zins M; Ozguler A; Rigal L
Nutr Metab Cardiovasc Dis; 2023 Jun; 33(6):1254-1262. PubMed ID: 37088650
[TBL] [Abstract][Full Text] [Related]
2. Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets' attainment in subjects with and without type 2 diabetes.
Morieri ML; Perrone V; Veronesi C; Degli Esposti L; Andretta M; Plebani M; Fadini GP; Vigili de Kreutzenberg S; Avogaro A
Cardiovasc Diabetol; 2021 Jul; 20(1):144. PubMed ID: 34271920
[TBL] [Abstract][Full Text] [Related]
3. Relative contributions of statin intensity, achieved low-density lipoprotein cholesterol level, and statin therapy duration to cardiovascular risk reduction in patients with type 2 diabetes: population based cohort study.
Kim JY; Choi J; Kim SG; Kim NH
Cardiovasc Diabetol; 2022 Feb; 21(1):28. PubMed ID: 35193571
[TBL] [Abstract][Full Text] [Related]
4. Sex disparity persists in the prevention of cardiovascular disease in women on statin therapy compared to that in men.
Moreno-Arellano S; Delgado-de-Mendoza J; Santi-Cano MJ
Nutr Metab Cardiovasc Dis; 2018 Aug; 28(8):810-815. PubMed ID: 29754716
[TBL] [Abstract][Full Text] [Related]
5. Assessment of Sex Disparities in Nonacceptance of Statin Therapy and Low-Density Lipoprotein Cholesterol Levels Among Patients at High Cardiovascular Risk.
Brown CJ; Chang LS; Hosomura N; Malmasi S; Morrison F; Shubina M; Lan Z; Turchin A
JAMA Netw Open; 2023 Feb; 6(2):e231047. PubMed ID: 36853604
[TBL] [Abstract][Full Text] [Related]
6. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of Low-density Lipoprotein Cholesterol Level-Guided Statin Treatment in Patients With Borderline Cardiovascular Risk.
Kohli-Lynch CN; Bellows BK; Thanassoulis G; Zhang Y; Pletcher MJ; Vittinghoff E; Pencina MJ; Kazi D; Sniderman AD; Moran AE
JAMA Cardiol; 2019 Oct; 4(10):969-977. PubMed ID: 31461121
[TBL] [Abstract][Full Text] [Related]
8. [Screening for hyperlipidemia in cardiovascular high-risk patients in austrian diabetes ambulances].
Brath H; Wascher TC; Kästenbauer T; Toplak H
MMW Fortschr Med; 2012 Jun; 154 Suppl 2():41-7. PubMed ID: 23424754
[TBL] [Abstract][Full Text] [Related]
9. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels.
Querton L; Buysschaert M; Hermans MP
J Clin Lipidol; 2012; 6(5):434-42. PubMed ID: 23009779
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011-2012.
Wong ND; Young D; Zhao Y; Nguyen H; Caballes J; Khan I; Sanchez RJ
J Clin Lipidol; 2016; 10(5):1109-18. PubMed ID: 27678427
[TBL] [Abstract][Full Text] [Related]
11. Non-achievement of LDL-cholesterol targets in patients with diabetes at very-high cardiovascular risk receiving statin treatment: Incidence and risk factors.
Breuker C; Clement F; Mura T; Macioce V; Castet-Nicolas A; Audurier Y; Boegner C; Morcrette E; Jalabert A; Villiet M; Avignon A; Sultan A
Int J Cardiol; 2018 Oct; 268():195-199. PubMed ID: 30041785
[TBL] [Abstract][Full Text] [Related]
12. Utilization of statins and LDL-cholesterol target attainment in Turkish patients with type 2 diabetes - a nationwide cross-sectional study (TEMD dyslipidemia study).
Bayram F; Sonmez A; Haymana C; Sabuncu T; Dizdar OS; Gurkan E; Carlioglu AK; Agbaht K; Ozdemir D; Demirci I; Barcin C; Salman S; Tetiker T; Balci MK; Kebapci N; Ersoy C; Yumuk V; Toth PP; Satman I;
Lipids Health Dis; 2020 Nov; 19(1):237. PubMed ID: 33176832
[TBL] [Abstract][Full Text] [Related]
13. Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial.
Giugliano RP; Keech A; Murphy SA; Huber K; Tokgozoglu SL; Lewis BS; Ferreira J; Pineda AL; Somaratne R; Sever PS; Pedersen TR; Sabatine MS
JAMA Cardiol; 2017 Dec; 2(12):1385-1391. PubMed ID: 29117276
[TBL] [Abstract][Full Text] [Related]
14. A Long-term Benefit Approach vs Standard Risk-Based Approaches for Statin Eligibility in Primary Prevention.
Thanassoulis G; Sniderman AD; Pencina MJ
JAMA Cardiol; 2018 Nov; 3(11):1090-1095. PubMed ID: 30422172
[TBL] [Abstract][Full Text] [Related]
15. Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy.
Furuhashi M; Sakuma I; Morimoto T; Higashiura Y; Sakai A; Matsumoto M; Sakuma M; Shimabukuro M; Nomiyama T; Arasaki O; Node K; Ueda S
Cardiovasc Diabetol; 2020 Jun; 19(1):89. PubMed ID: 32539832
[TBL] [Abstract][Full Text] [Related]
16. Race-Sex Differences in Statin Use and Low-Density Lipoprotein Cholesterol Control Among People With Diabetes Mellitus in the Reasons for Geographic and Racial Differences in Stroke Study.
Gamboa CM; Colantonio LD; Brown TM; Carson AP; Safford MM
J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28490523
[TBL] [Abstract][Full Text] [Related]
17. Cholesterol levels and development of cardiovascular disease in Koreans with type 2 diabetes mellitus and without pre-existing cardiovascular disease.
Kim MK; Han K; Joung HN; Baek KH; Song KH; Kwon HS
Cardiovasc Diabetol; 2019 Oct; 18(1):139. PubMed ID: 31640795
[TBL] [Abstract][Full Text] [Related]
18. Retrospective examination of lipid-lowering treatment patterns in a real-world high-risk cohort in the UK in 2014: comparison with the National Institute for Health and Care Excellence (NICE) 2014 lipid modification guidelines.
Steen DL; Khan I; Ansell D; Sanchez RJ; Ray KK
BMJ Open; 2017 Feb; 7(2):e013255. PubMed ID: 28213597
[TBL] [Abstract][Full Text] [Related]
19. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
[TBL] [Abstract][Full Text] [Related]
20. Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany.
März W; Dippel FW; Theobald K; Gorcyca K; Iorga ŞR; Ansell D
Atherosclerosis; 2018 Jan; 268():99-107. PubMed ID: 29197254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
